Genetic Technologies Limited
GENE · NASDAQ
6/30/2024 | 12/31/2023 | 6/30/2023 | 12/31/2022 | |
|---|---|---|---|---|
| Market Cap | $0 | $0 | $0 | $0 |
| - Cash | $0 | $0 | $0 | $0 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | $0 | $0 | $0 | $0 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | 21.2% | -12.7% | 9.1% | – |
| Gross Profit | $0 | -$0 | -$0 | -$0 |
| % Margin | 58.3% | -50% | -27% | -37.2% |
| EBITDA | -$0 | -$0 | -$0 | -$0 |
| % Margin | -110.5% | -123.3% | -131.1% | -121.8% |
| Net Income | -$0 | -$0 | -$0 | -$0 |
| % Margin | -116.6% | -162.2% | -138.8% | -131.4% |
| EPS Diluted | -1.13 | -1.59 | -1.95 | -1.69 |
| % Growth | 28.9% | 18.5% | -15.4% | – |
| Operating Cash Flow | -$0 | -$0 | -$0 | -$0 |
| Capital Expenditures | -$0 | -$0 | -$0 | -$0 |
| Free Cash Flow | -$0 | -$0 | -$0 | -$0 |